Juvéderm Volbella XC treatment for lip and perioral enhancement was safe and effective, with the effects of treatment lasting through 1 year, according to study results published in Dermatologic Surgery.
Roy G. Geronemus, MD, of the Laser & Skin Surgery Center of New York, and colleagues conducted a randomized study of 225 adults (median age, 54 years; 96.9% women) with minimal, mild or moderate lip fullness, using a validated 5-point Allergan Lip Fullness Scale (LFS). One hundred and sixty-nine patients were treated with Juvéderm Volbella XC (nonaminal crosslinked hyaluronic acid [HA] gel with lidocaine; Allergan; VYC-15), and 56 patients were treated with Restylane-L (nonaminal stabilized HA with lidocaine; NASHA; Medicis Aesthetics).
Roy G. Geronemus
Optional touch-up treatment was administered at 1 month, with follow-up for 1 year.
Noninferiority of VYC-15L versus NASHA by mean change in LFS score from baseline to month 3 was primary endpoint.
The LFS responder rates at month 3 were 80.3% for patients treated with VYC-15L compared with 70.8% for NASHA-treated patients. The patients treated with VYC-15L had LFS responder rates exceeding 60% through 1 year.
The patients treated with VYC-15L had perioral line severity improvement of 65.4% at 3 months and of 66.2% at 1 year. Improvement in FASE-Q Satisfaction with Lips and Satisfaction with Lip Lines were reported by 96.1% and 88.2% patients in the VYC-15L cohort, respectively.
Common injection site responses included swelling, firmness, and lumps and bumps, with rates being 5 percentage points or more for patients treated with VYC-15L compared with NASHA for redness, pain after injection, itching and discoloration. The VYC-15L cohort had less frequently reported severe ISRs (46.1%) compared with the NASHA group (56%).
“These findings illustrate the effectiveness of VYC-15L for lip and perioral enhancement.,” the researchers wrote. “This study shows that YVC-15L is safe and effective for lip and perioral enhancement, with treatment effects persisting through 1 year.” – by Bruce Thiel
Disclosure: The study was supported by Allergan. Geronemus reports being an investigator for Allergan. Please see the full study for a list of other researchers’ relevant financial disclosures.